Adagio Medical Holdings, Inc. Annual Report: A Simple Guide

I’ve put together this plain-English guide to help you understand Adagio Medical’s performance. My goal is to turn complex financial filings into clear information so you can decide if this company fits your investment strategy.

1. What does this company do?

Adagio Medical creates technology to treat heart rhythm disorders, specifically atrial fibrillation (AFib) and atrial flutter. They make the vCLAS™ and vTRAC™ catheters, which plug into their iCLAS™ cryoablation console. While traditional methods use heat, Adagio uses pulsed field cryoablation (PFCA) to freeze heart tissue. They provide tools for heart specialists to perform faster procedures and improve long-term patient results.

2. The Big Picture

Adagio is in a high-stakes transition. After merging with ARYA Sciences Acquisition Corp IV on June 14, 2024, the company began trading on the Nasdaq as "ADGM." They spent the rest of 2024 and 2025 integrating these businesses and scaling up operations.

They are currently in a "growth and survival" phase. They cleaned up their balance sheet by converting about $135 million in old debt into company stock. As of March 2026, they had about 22.2 million shares outstanding. The company is moving from a startup to a public, commercial business.

3. Financial Health: The Cash Situation

Adagio is not yet profitable. For the year ending December 31, 2025, they reported an operating loss of about $48 million. This came mostly from $25 million in research costs and $15 million in general business expenses.

To keep running, they rely on:

• Financing: After the merger, they raised about $50 million from private investors to fund operations.
• Cash Burn: The company spends about $3.5 million to $4 million per month. Their survival depends on having enough cash for at least 12 months, which means they must keep raising money.

4. Key Risks

• Funding Dependency: Because they aren't profitable, they are sensitive to market changes. If the stock price stays low, raising more money becomes expensive, which threatens their ability to keep operating.
• Supply Chain: They rely on a single source for critical parts. If their factory or a key supplier has a problem, they could be unable to sell products for months.
• Dilution: They have many outstanding warrants and notes. If these are used, the company will issue more shares, which reduces your ownership percentage.
• Regulatory Hurdles: They are waiting for final FDA approval for their main products. Any delays in clinical data or requests for more studies could push their launch back by 12 to 18 months. During that time, they would continue to lose money without any sales.

5. Future Outlook

The company is focused on moving past the merger and into full-scale sales. Their success depends on hospitals choosing their technology over industry giants like Johnson & Johnson and Boston Scientific. To win, Adagio must prove their system is cheaper to use and keeps patients healthier than current options.

Final Thought for Investors: When considering an investment in Adagio, ask yourself if you are comfortable with the risks of a pre-profit medical device company. Success hinges on two major milestones: securing final regulatory approvals and successfully competing against established, multi-billion-dollar medical device manufacturers. If you believe their PFCA technology offers a clear advantage that hospitals will adopt, the current "growth and survival" phase may represent an entry point—but keep a close eye on their monthly cash burn and future funding announcements.